Dodd, Michael Berk, Julie Pasco, David Ashley, Yann Gibert, Lana Williams ... Sandra Isenmann, Stan Gronthos, Paul Anderson, Howard Morris, Gerald J. Atkins.
ANZBMS 23rd Annual Scientific Meeting 8 - 11 SEPTEMBER 2013 HILTON ON THE PARK, MELBOURNE, VICTORIA
Meeting Handbook PLATINUM SPONSORS
ANZBM S 23 rd ANNUAL SCIENTIFIC M EETING – SCIENTIFIC PROGRAM P36
EGFL7 expressed in bone microenvironment mediates the migration of endothelial cells via ERK, STAT3 and integrin signaling cascades Shek Man Chim, Vincent Kuek, Siu to Chow, Bay Sie Lim, Jennifer Tickner, Rosa Chung, Yu-Wen Su, Ge Zhang, Wendy Erber, Vicki Rosen, Cory Xian, Jiake Xu
P37
The role of EGFL6 in bone homeostasis Shek Man Chim, Jennifer Tickner, Baysie Lim, Benjamin Ng, Jiake Xu
P38
Anabolic action on bone cells by the coiled-coil domain of fasting-induced adipose factor (FIAFCCD) JM Lin, D Naot, JL Costa, AB Grey, J Cornish
P39
Osteoclast gp130 signalling stimulates periosteal bone formation Rachelle Johnson, Narelle McGregor, Holly Brennan, Ingrid Poulton, T John Martin, Natalie A Sims
P40
Cell death is augmented in ephrinB2-deficient osteoblasts Blessing Crimeen-Irwin, Stephen Tonna, Patricia WM Ho, T John Martin, Natalie A Sims
P41
End-products of a tryptophan degradation pathway have an osteo-anabolic effect on differentiating mesenchymal stem cells Christopher Vidal, Sandra Bermeo, Wei Li, Krishanthi Gunaratnam, Gilles Guillemin, Chai Lim, Gustavo Duque
P42
Analysis of bone formation activity utilizing transgenic mice by in vivo bioluminescence imaging Tomoko Nakanishi, Kazuo Kokubun, Haruka Oda, Mika Aoki, Makoto Taniguchi, Atsumi Soma, Yasuhiro Kazuki, Mitsuo Oshimura
P43
Selective serotonin reuptake inhibitors (SSRIs) inhibit human osteoblastogenesis and decrease bone development and mineralization in Zebrafish Jason Hodge, Daniel Fraher, Fiona Collier, Janine McMillan, Lee Kennedy, Megan Ellis, Ken Walder, Seetal Dodd, Michael Berk, Julie Pasco, David Ashley, Yann Gibert, Lana Williams
P44
A novel mouse cortical bone derived mesenchymal stem cell-like cell line Dongqing Yang, Sandra Isenmann, Stan Gronthos, Paul Anderson, Howard Morris, Gerald J. Atkins
P45
Molecular mechanisms underlying accelerated bone remodeling during hyperhomocysteinemia Viji Vijayan, Mayuri Khandelwal, Kapil Manglani, Rajiv Ranjan Singh, Sarika Gupta, Avadhesha Surolia
P46
The effects of 17β-estradiol on cellular proliferation and calcification of human mesenchymal stem cell during osteogenesis Jenny Wang, Joshua Lewis, Lawrence Liew, Anthony Buzzai, Rodney Dilley, Jeremy Tan, Gerard Hardisty, Jeffery Hamdorf, Minghao Zheng, Richard Prince
P47
MicroRNAs & cell signaling pathways: orchestrating osteogenesis and osseointegration Nishant Chakravorty, Anjali Jaiprakash, Ross Crawford, Adekunle Oloyede, Saso Ivanovski, Yin Xiao
P48
The roles of Schnurri family in differentiation of osteoblasts and chondrocytes Katsuyuki Imamura, Shingo Maeda, Ishidou Yasuhiro, Masahiro Yokouchi, Setsuro Komiya
P49
The direct anti-anabolic effect of sclerostin on the mechanical loading response in bovine bone ex vivo Masakazu Kogawa, Kamarul A Khalid, Asiri R Wijenayaka, Renee T Ormsby, David M Findlay, Gerald J Atkins
P50
The characterisation of SaOS2 osteosarcoma cells as an in vitro osteocyte-like cell model Matthew Prideaux, David M. Findlay, Asiri R. Wijenayaka, Duminda Kumarasinghe, Gerald J. Atkins
P51
What determines osteocyte density in bone matrix? A computational model Pascal R Buenzli, C David L Thomas, John G Clement
P52
Global deletion of the cyp27b1 gene results in impaired osteoclastogenesis and activity in splenocyte cultures generated ex vivo from mouse knockout models Daniel Reinke, Masakazu Kogawa, Paul Anderson, Howard Morris, Gerald Atkins
P53
Histological localization of 15N-minodronate by isotope microscopy and its biological effects on bone cells Muneteru Sasaki, Hiromi Hongo, Sachio Kobayashi, Hisayoshi Yurimoto, Norio Amizuka
P54
Antipsychotics inhibit human osteoclast formation and function Alice Torpy, Jason Hodge, Fiona Collier, Julie Pasco, Michael Berk, David Ashley, Lana Williams
Hilton on the Park • Melbourne
19
8-11 September 2013
ANZBM S 23 rd ANNUAL SCIENTIFIC M EETING
! P44 A novel mouse cortical bone derived mesenchymal stem cell-like cell line 1 2 3 4 4 1 Dongqing Yang , Sandra Isenmann , Stan Gronthos , Paul Anderson , Howard Morris , Gerald J. Atkins 1 2 Centre for Orthopaedic Trauma Research, University of Adelaide, Mesenchymal Stem Cell Laboratory, 3 School of Medical Sciences, University of Adelaide, 2Mesenchymal Stem Cell Laboratory, School of 4 Medical Sciences, University of Adelaide, School of Pharmacy and Medical Sciences, University of South Australia Mesenchymal stem cells (MSCs) are multi-potent cells that can be differentiated to various cell lineages including osteoblast, adipocyte, chondrocyte and smooth muscle. Cell lines with MSC-like characteristics and that can form mineralising osteoblasts have not been reported previously. Here we report the characterisation of a novel murine cell line with MSC-like properties. Cells were derived from the culture of 4-week old C57BL/6 mouse long bone cortices plated ex vivo. After repeated passage, one such culture spontaneously exhibited transformed properties evidenced by maintenance of proliferative potential up to at least passage 25. Subsequent analysis revealed strong activity of telomerase remaining up to at least passage 7. These cells had uniform morphology and were positive for type 1 collagen and negative for the macrophage marker, F4/80. Further immunophenotyping showed them to be negative for the haemopoietic markers CD11b and CD45, the haemopoietic stem cell marker, CD34, and the endothelial marker CD31. A panel of MSC markers including Sca1, CD44, CD73, CD146, CD166 were highly expressed. The cell line exhibited tumorigenic properties and was able to differentiate towards mineralising osteoblasts, lipid forming adipocytes and collagen type II producing chondrocytes using both in vitro culture models and an in vivo sub-cutaneous implantation model. We conclude that this cell line, designated MMSC-13, is a spontaneous osteosarcoma-like population with MSC-like properties having the ability of forming osteoblasts, adipocytes and chondrocytes in vitro and in vivo. This cell line is a potentially useful tool for studying the differentiation of MSC into mineralising osteoblasts. P45 Molecular mechanisms underlying accelerated bone remodeling during hyperhomocysteinemia 1 1 1 1 1 2 Viji Vijayan , Mayuri Khandelwal , Kapil Manglani , Rajiv Ranjan Singh , Sarika Gupta , Avadhesha Surolia 1 2 National Institute of Immunology, Indian Institute of Science RANK ligand (receptor activator of nuclear factor-κB ligand) and osteoprotegerin (OPG) are two significant proteins synthesized by the osteoblast to regulate bone remodeling. The RANK ligand plays a major role in osteoclast formation, function and survival through its interaction with the RANK on the osteoclast and is physiologically regulated by OPG, a decoy receptor which interferes with RANKL-RANK association and inhibits osteoclast activity. Our investigations revealed that homocysteine mediated oxidative events alters the normal synthesis pattern of OPG and RANK ligand by the osteoblast. Homocysteine mediated OPG downregulation occurred through activation of protein phosphatase 2A (PP2A), a negative modulator of the insulin signaling pathway which induced dephosphorylation of redox regulator FOXO1 (Ser253 and Tyr24), FOXO1 nuclear localization, MnSod expression and p38 MAP kinase downregulation. On the other hand, an increased expression and release of RANK ligand in homocysteine treated osteoblast cultures occurred by a mechanism independent of FOXO1/p38 signaling but involving c-Jun/JNK MAP kinase (JNK) signaling pathway. FOXO1 expression and OPG:RANKL ratio were low in bone milieu of hyperhomocysteinemic rats. By FOXO1 siRNA knockdown experiments we were able to prove that FOXO1 is integral to both OPG and p38 synthesis but not RANK ligand. Our results shed light on the underlying mechanisms for diminished osteoblast function and bone formation during hyperhomocysteinemia and also points out that modulation of PP2A/ FOXO1/MAP kinase pathway is a potentially useful therapeutic mechanism for curbing increased bone remodeling during disease pathologies like hyperhomocysteinemia
Hilton on the Park• Melbourne
8-11September2013
